WO2013039374A2 - Procédé d'extraction, d'essai et de comptage d'extrait dialysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant que traitement contre la maladie connue sous le nom de vitiligo - Google Patents
Procédé d'extraction, d'essai et de comptage d'extrait dialysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant que traitement contre la maladie connue sous le nom de vitiligo Download PDFInfo
- Publication number
- WO2013039374A2 WO2013039374A2 PCT/MX2012/000085 MX2012000085W WO2013039374A2 WO 2013039374 A2 WO2013039374 A2 WO 2013039374A2 MX 2012000085 W MX2012000085 W MX 2012000085W WO 2013039374 A2 WO2013039374 A2 WO 2013039374A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leukocyte
- transfer factor
- extract
- vitiligo
- leukocyte extract
- Prior art date
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 58
- 108010074506 Transfer Factor Proteins 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 title claims abstract description 34
- 206010047642 Vitiligo Diseases 0.000 title claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 27
- 241000251730 Chondrichthyes Species 0.000 title claims abstract description 26
- 210000000952 spleen Anatomy 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 10
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 12
- 210000000987 immune system Anatomy 0.000 claims abstract description 11
- 210000004324 lymphatic system Anatomy 0.000 claims abstract 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 42
- 210000002752 melanocyte Anatomy 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000000502 dialysis Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 10
- 241000699670 Mus sp. Species 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 208000012641 Pigmentation disease Diseases 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 230000005284 excitation Effects 0.000 claims description 4
- 229940047122 interleukins Drugs 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 238000012792 lyophilization process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000005457 optimization Methods 0.000 claims description 2
- 238000007434 physicochemical evaluation Methods 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000005057 refrigeration Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 7
- 230000006698 induction Effects 0.000 claims 3
- 206010002536 Anisocytosis Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000005965 immune activity Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000000386 microscopy Methods 0.000 claims 1
- 238000012797 qualification Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- HJMIIBXYFPJZBP-UHFFFAOYSA-N 10-(2,3,4,5-tetrahydroxypentyl)-1h-pyrimido[4,5-b]quinoline-2,4,8-trione Chemical compound N1C(=O)NC(=O)C2=C1N(CC(O)C(O)C(O)CO)C1=CC(=O)C=CC1=C2 HJMIIBXYFPJZBP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- the present invention relates to a leukocyte extract containing polypeptides equal to or less than 10,000 daltons of shark spleen origin and its use as a medicament in the treatment of the disease known as vitiligo.
- Vitiligo is a degenerative skin disease in which melanocytes (the cells responsible for skin pigmentation) die, thus stopping producing melanin (the substance that produces skin pigmentation) in the area where it has occurred cell death
- the autoimmune theory Melanocytes are destroyed by certain activated lymphocytes. It would be similar to what happens in other better known autoimmune processes (such as some thyroiditis), and is confirmed by the response of some cases to treatments with immunosuppressive drugs.
- Neurogenic theory A possible interaction between melanocytes and nerve cells that would release a toxic neurochemical mediator is postulated. This would be the cause of the destruction of melanocytes.
- vitiligo is caused by the increase in the amount of adrenaline in the bloodstream that causes an overload in the functioning of the spleen, liver, kidney and pancreas, due to the excess of toxins (free radicals) that They are not able to eliminate.
- a potentialized transfer factor specifically designed for use as a treatment against the disease known as vitiligo.
- the means for obtaining a dialysable leukocyte extract containing polypeptides less than or equal to 10,000 Daltons whose source or origin is from shark cells, tissues or organs, more specifically shark spleen, of the present invention, is considered novel.
- the potentialized transfer factor of the present invention is specifically obtained for the treatment of the symptomatology of the disease known as vitiligo, since it has the ability to reactivate the cells, specifically the individual's immune system, which gives the body the ability to reactivate the cells responsible for skin pigmentation, that is to say melanocytes, and therefore balance the production of melanin in the skin through such activation mobile.
- the Potentialized Transfer Factor specifically designed for the medical treatment of the disease known as vitiligo of the present invention helps neurotransmitters restore chemical signals that travel from the brain to the bone marrow, so that, as is known in the state of the art of the transfer factor, this is coupled to the chemical signals of the neui'otransmors so as to potentiate the signal, which manages to establish the correct chemical signaling to the melanocytes and thus "order" that they begin to produce melanin.
- the melanocytes are forced to restore the correct levels of melanin production in order to achieve pigmentation of the depigmented areas by the low amount of melanin and therefore treat a disease known as vitiligo.
- the transfer factor of the present invention by continuous administration of the transfer factor of the present invention, the typical symptomatology of the disease known as vitiligo can be eliminated, since by helping the chemical signals travel from the brain to the bone marrow, the white blood cell production, which are the raw material for the production of melanocytes and these in turn are responsible for producing melanin, which is the latter deficiency found in the skin of patients with the disease known as vitiligo. It is well known for an expert in the state of the art, that the transfer factor has as its main function to help the production and proper restoration of white cells and their excitation, in order to achieve the optimal functioning of the immune system.
- the potentialized transfer fac.ci of the present invention helps the treatment of the known disease with the name of vitiligo, since it gives the possibility of alleviating the characteristic symptomatology thereof, by means of cell excitation immune system of the individual and correct operation of ios neurotransmitters, which are responsible chemical signals of various body functions, including prod j ction ae lancos globules c leukocytes which in turn result among other things in melanocytes and in turn melanin.
- the Transfer Factor Fo.er.cia raised for the treatment of the disease known as vitiligo of the present invention, consists of a potency of 10 12 leukocytes x mm 3 (understood as potency to the quantity of leukocytes and quality of the smooth, round and innocuous cells)), quantity necessary for leukocyte excitation and optimization of chemical signals for the production of white blood cells , which in turn produce melanocytes and the latter melanin.
- Figure 1 shows the type of cytosines induced from the inoculation of the eucocyte extract in Balb-c mice.
- the leukocyte extract after the separation and rupture of components has been carried out, is placed in a semipermeable dialysis bag, as for example, in a cellulose membrane with pores, and the bag is sealed.
- the sealed dialysis bag is placed in a container with a different solution, or pure water.
- the leukocyte extract being small enough to pass through the pores, tends to move in or out of the dialysis bag in the direction of the lowest concentration. Larger molecules (often proteins, DNA, or polysaccharides) that have dimensions significantly larger than the pore diameter are retained within the dialysis bag. In this way, leukocyte extracts less than or equal to 10,000 Daltons are separated.
- the leukocyte extract is filtered through a pore size membrane between 2 and 4 micrometers. Also, the solution is sterilized again.
- Formulation.- A lyophilization process is carried out to remove the water from the leukocyte extract through the generation of a vacuum, likewise in this step the aggregation of a vehicle is carried out, such as milk, water, gel or artificial flavoring, to give a presentation and pleasant taste to the product.
- a vehicle such as milk, water, gel or artificial flavoring
- the cytosines required for the treatment of the disease known as vitiligo are induced, this from the dilution of the leukocyte extract until reaching the title of the cytosines required for the production of interleukins that activate the melanocytes and therefore, level the production of melanin in the subject, thus achieving pigmentation of depigmented areas due to the lack or lack of melanin.
- the leukocyte extract with mtcroarray membranes is also analyzed to determine the type of cytokine found in the leukocyte extract.
- the result of the above process is a potentialized transfer factor specifically designed for the treatment of the disease known as vitiligo by administering the appropriate cytosine (s) for the activation of melanocytes that will produce melanin and thus repigment areas depigmented by the lack of melanin
- the transfer factor of the present invention is in powder form, which gives it the virtue of being easily transported and stored, does not require refrigeration and a transfer factor power of 10 12 leukocytes x mm 3 is obtained , which It is highly superior to any known transfer factor, understood as leukocyte potency concentration per mm 3 and cell quality (smooth, round and innocuous).
- Figure 1 illustrates the type of cytosines induced from inoculation of the leukocyte extract in Balb-c mice. Where groups of 8 mice are used, which will be inoculated with the equivalent amount to the weight-unit ratio of transfer factor (0.005 unit of transfer factor).
- Whey is extracted from each mouse, 50 microliters of serum are used, exposed against the microarray membranes that contain the cytosine receptor antibodies and the wells that develop color will be induced cytosines.
- the serum is diluted with a regulatory solution in multiples of 2 initially and then diluted in multiples of 100.
- the baseline dilution of time 0 and the dilution that preserves the color development in the microarrays prior to dilution where it is no longer present is eliminated. Color development is the title of the leukocyte extract.
Abstract
L'invention concerne un extrait leucocytaire qui contient des polypeptides dont la masse moléculaire est inférieure ou égale à 10 000 daltons et qui provient de rate de requin et son utilisation en tant que médicament dans le traitement de la maladie connue sous le nom de vitiligo. Ledit extrait est un extrait dialysable de leucocytes, dont la source spécifique est la rate qui fait partie du spécifique lymphatique et qui est le centre d'activité du système immunitaire des sélachimorphes, lesquels représentent le super-ordre des chondrichthyens, communément connus sous le nom de squales, pour l'obtention du facteur de transfert potentialisé.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535089P | 2011-09-15 | 2011-09-15 | |
| US61/535,089 | 2011-09-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013039374A2 true WO2013039374A2 (fr) | 2013-03-21 |
| WO2013039374A3 WO2013039374A3 (fr) | 2013-05-02 |
Family
ID=47883903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/MX2012/000085 WO2013039374A2 (fr) | 2011-09-15 | 2012-09-13 | Procédé d'extraction, d'essai et de comptage d'extrait dialysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant que traitement contre la maladie connue sous le nom de vitiligo |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2013039374A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016195468A1 (fr) * | 2015-06-04 | 2016-12-08 | Zepeda López Héctor Manuel | Modulateur de lymphocytes t potentialisé, capable de moduler la réponse immunitaire, spécifiquement conçu pour l'utilisation thérapeutique dans le traitement de la maladie connue comme vitiligo |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080081076A1 (en) * | 2006-09-29 | 2008-04-03 | Lisonbee David A | Nanofraction immune modulators, preparations and compositions including the same, and associated methods |
| US20080206171A1 (en) * | 2007-02-26 | 2008-08-28 | L'oreal | Conditioned medium and uses thereof |
| MX2008009296A (es) * | 2008-07-18 | 2010-01-18 | Carlos Adolfon Perez De La Mora | Procedimiento optimizado para la obtencion del extracto dializable leucocitario que contiene peptidos con peso molecular igual o inferior a 10,000 daltones, a partir de tejido linfoide de cocodrilo y su preparación en una forma farmaceutica oral y/o |
| ES2353208T3 (es) * | 2002-02-28 | 2011-02-28 | Luis Antonio Calzada Nova | Extracto dializado de leucocitos para el tratamiento de enfermedades infecciosas en animales. |
-
2012
- 2012-09-13 WO PCT/MX2012/000085 patent/WO2013039374A2/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2353208T3 (es) * | 2002-02-28 | 2011-02-28 | Luis Antonio Calzada Nova | Extracto dializado de leucocitos para el tratamiento de enfermedades infecciosas en animales. |
| US20080081076A1 (en) * | 2006-09-29 | 2008-04-03 | Lisonbee David A | Nanofraction immune modulators, preparations and compositions including the same, and associated methods |
| US20080206171A1 (en) * | 2007-02-26 | 2008-08-28 | L'oreal | Conditioned medium and uses thereof |
| MX2008009296A (es) * | 2008-07-18 | 2010-01-18 | Carlos Adolfon Perez De La Mora | Procedimiento optimizado para la obtencion del extracto dializable leucocitario que contiene peptidos con peso molecular igual o inferior a 10,000 daltones, a partir de tejido linfoide de cocodrilo y su preparación en una forma farmaceutica oral y/o |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016195468A1 (fr) * | 2015-06-04 | 2016-12-08 | Zepeda López Héctor Manuel | Modulateur de lymphocytes t potentialisé, capable de moduler la réponse immunitaire, spécifiquement conçu pour l'utilisation thérapeutique dans le traitement de la maladie connue comme vitiligo |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013039374A3 (fr) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Azeem et al. | Anti–inflammatory activity of the glandular extracts of Thunnus alalunga | |
| Bocci | OZONE. | |
| Di Cesare Mannelli et al. | Therapeutic effects of the superoxide dismutase mimetic compound me 2 DO2A on experimental articular pain in rats | |
| McBride et al. | Reduction of cerebral edema after traumatic brain injury using an osmotic transport device | |
| Chien et al. | A Chinese herbal medicine, Jia-Wei-Xiao-Yao-San, prevents dimethylnitrosamine-induced hepatic fibrosis in rats | |
| US10335538B2 (en) | System and treatment method to increase circulation and pluripotency of stem and progenitor cells within a patient | |
| Turdiyev et al. | CHOLERETIC ACTIVITY OF RUTANA AT THERAPEUTIC APPLICATION IN RATS WITH HELIOTRIN HEPATITIS | |
| Gok et al. | Is it possible to remove heavy metals from the body by wet cupping therapy (Al-hijamah)? | |
| ES2685374T3 (es) | Nueva composición para la reducción extracorpórea de beta amiloides y procedimiento de producción de la misma | |
| WO2013043032A2 (fr) | Extrait dialysé de leucocytes issu de rate de requin utilisé pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant qu'immunomodulateur et procédé d'extraction, d'essai et de comptage de ce dernier | |
| El-Mahalaway et al. | The potential protective effect of propolis on experimentally induced hepatitis in adult male albino rats. Histological and immunohistochemical study | |
| Sharma et al. | Rodent spinal cord injury model and application of neurotrophic factors for neuroprotection | |
| WO2013039374A2 (fr) | Procédé d'extraction, d'essai et de comptage d'extrait dialysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant que traitement contre la maladie connue sous le nom de vitiligo | |
| CN101054414B (zh) | 鹿茸表皮生长因子(deer egf)提取及其制备方法 | |
| Khatab et al. | samar. zag1234@ gmail. com | |
| KR101599907B1 (ko) | 천연 원료 추출물을 포함하는 항산화제 및 이의 용도 | |
| CN103690935A (zh) | 一种含有胸腺法新的冻干药物组合物及制备方法 | |
| CN105132503B (zh) | 石龟活性肽精制法及在预防肝硬化、抗疲劳中的应用 | |
| Tylicki et al. | Platelet function unaffected by ozonated autohaemotherapy in chronically haemodialysed patients | |
| Han et al. | Acute and 90-day subchronic toxicity studies of Silk peptide E5K6, in Sprague–Dawley rats | |
| CN114848836B (zh) | 一种偶联物及其在治疗内耳疾病上的应用 | |
| Prohp et al. | Effects of aqueous extract of Triplochiton scleroxylon on red blood cells and associated parameters in alloxan-induced diabetic rabbits | |
| WO2013043033A2 (fr) | Procédé d'extraction et d'essai d'extrait dialiysé de leucocytes provenant de rate de requin, pour obtenir un facteur de transfert potentialisé, spécifiquement conçu pour être utilisé en tant qu'adjuvant potentialisateur de vaccins viraux | |
| RU2526172C2 (ru) | Лечебное средство профилактики и лечения хронических заболеваний печени | |
| EA035673B1 (ru) | Смесь для лечения патологий, ассоциированных с лимфатической гиперпроницаемостью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12831506 Country of ref document: EP Kind code of ref document: A2 |